[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572244":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":36,"centralContacts":39,"locations":47,"responsibleParty":125,"collaborators":11,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":11,"eligibilityCriteria":133,"healthyVolunteers":129,"sex":134,"minAge":135,"maxAge":11,"enrollmentInfo":136,"targetDuration":11,"studyType":139,"phases":140,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":94,"whyStopped":11,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14,17,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1A","EXPERIMENTAL",null,[13],"Drug: BMS-986490",{"label":15,"type":10,"description":11,"interventionNames":16},"Part 2A - Colorectal Cancer (CRC)",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Part 2A - Non-Small Cell Lung Cancer\u002FGastric Cancer (NSCLC\u002FGC)",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Part 1B",[13,23],"Drug: Bevacizumab",{"label":25,"type":10,"description":11,"interventionNames":26},"Part 2B",[13,23],[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","BMS-986490","Specified dose on specified days.",[9,21,15,18,25],{"type":29,"name":34,"description":31,"armGroupLabels":35,"otherNames":11},"Bevacizumab",[21,25],[37],{"name":5,"affiliation":5,"role":38},"STUDY_DIRECTOR",[40,45],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":46,"role":42,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[48,62,72,82,92,109],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":11},"Local Institution - 0007","ACTIVE_NOT_RECRUITING","Los Angeles","California","90033","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-118.24368,34.05223,{"lat":60,"lon":59},{"facility":63,"status":50,"city":64,"state":65,"zip":66,"country":54,"countryCode":55,"cosmosGeoPoint":67,"geoPoint":71,"contacts":11},"Local Institution - 0017","Grand Rapids","Michigan","49546",{"type":57,"coordinates":68},[69,70],-85.66809,42.96336,{"lat":70,"lon":69},{"facility":73,"status":50,"city":74,"state":75,"zip":76,"country":54,"countryCode":55,"cosmosGeoPoint":77,"geoPoint":81,"contacts":11},"Local Institution - 0004","Hackensack","New Jersey","07601",{"type":57,"coordinates":78},[79,80],-74.04347,40.88593,{"lat":80,"lon":79},{"facility":83,"status":50,"city":84,"state":85,"zip":86,"country":54,"countryCode":55,"cosmosGeoPoint":87,"geoPoint":91,"contacts":11},"Local Institution - 0006","Pittsburgh","Pennsylvania","15232",{"type":57,"coordinates":88},[89,90],-79.99589,40.44062,{"lat":90,"lon":89},{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Tasman Oncology Research","RECRUITING","Southport","Queensland","4215","Australia","AU",{"type":57,"coordinates":101},[102,103],153.39796,-27.96724,{"lat":103,"lon":102},[106],{"name":107,"role":42,"phone":108,"phoneExt":11,"email":11},"Andrew Hill, Site 0012","+61756132480",{"facility":110,"status":94,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":57,"coordinates":117},[118,119],-79.39864,43.70643,{"lat":119,"lon":118},[122],{"name":123,"role":42,"phone":124,"phoneExt":11,"email":11},"Anna Spreafico, Site 0003","4169464501",{"type":126,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100572244","phase-1-a-study-of-bms-986490-with-or-without-bevacizumab-in-advanced-solid-tumors-100572244",false,"NCT06730750","A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","A Phase 1\u002F2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","Inclusion Criteria:\n\n* Documented histologically or cytologically confirmed, advanced, unresectable\u002Fmetastatic solid tumor measurable by RECIST v1.1.\n* CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:\n\n  i) Locally advanced\u002Fmetastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and\u002For oxaliplatin (if available and not contraindicated).\n* NSCLC: Part 2A-NSCLC\u002FGC, 2L+ NSCLC:\n\n  i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease.\n\nii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.\n\n\\- GC: Part 2A-NSCLC\u002FGC, 2L+ GC: i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy).\n\nii) ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n\n* History of anaphylactic reactions to irinotecan and\u002For bevacizumab.\n* Previously received therapy targeting CEACAM5.\n* Grade ≥3 ILD\u002Fpneumonitis.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":137,"type":138},360,"ESTIMATED","INTERVENTIONAL",[141,142],"PHASE1","PHASE2","This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.",[145],"Advanced Solid Tumors",[147,148,149],"Colorectal Cancer (CRC)","Non-small Cell Lung cancer (NSCLC)","Gastric Cancer (GC)","2026-07-01",{"date":152,"type":153},"2026-07-02","ACTUAL",{"date":155,"type":153},"2025-02-12",{"date":157,"type":138},"2029-12-09",{"name":5,"class":6},6]